Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elenestinib in indolent systemic mastocytosis
NL-OMON56049Phase 2Recruiting
- Sponsor
- Blueprint Medicines
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elenestinib in indolent systemic mastocytosis (ISM), systemic mastocytosis (SM) and monoclonal mast cell activation syndrome (MMAS) (11 arms), sponsored by Blueprint Medicines. Started Jul 2022; status: recruiting.
02
Drugs
elenestinib
03
Conditions
indolent systemic mastocytosis (ISM)systemic mastocytosis (SM)monoclonal mast cell activation syndrome (MMAS)
Beyond the preview
Go deeper on NL-OMON56049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56049.